Obrixtamig: Clinical Trials

3 trials of Obrixtamig, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 not yet recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 2, Not yet recruiting 1

Follow Obrixtamig: new trials by email Literature Review of Obrixtamig trials Research Report on Obrixtamig

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
Obrixtamig, Ezabenlimab, Atezolizumab - Advanced Cancer
Phase 3Not yet recruitingBoehringer Ingelheim682027-03-042026-11-10
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Obrixtamig, Carboplatin, Etoposide - Extrapulmonary Neuroendocrine Cancer (epNEC)
Phase 3RecruitingBoehringer Ingelheim3902026-07-102026-11-10
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
obrixtamig, atezolizumab, carboplatin - Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Phase 3RecruitingBoehringer Ingelheim6702026-04-132026-11-10

Conditions studied

Small Cell Lung Carcinoma (1)

Sponsors

Boehringer Ingelheim (3)

Countries

Belgium (3)  ·  France (3)  ·  Germany (3)  ·  Japan (3)  ·  Poland (3)  ·  Spain (3)  ·  Argentina (2)  ·  Australia (2)  ·  Austria (2)  ·  Brazil (2)  ·  Canada (2)  ·  Chile (2)  ·  China (2)  ·  Czechia (2)  ·  Finland (2)

NIH funding

2025 (2)